Mabion SA (272) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Mabioncd20 (Candidate Biosimilar To Rituximab), Mabthera®, Rituxan® | Rheumatoid Arthritis | Phase III | Withdrawn | MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis | Dec 02, 2020 | ― |
| Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone | Diffuse Large B-Cell Lymphoma | Phase III | Completed | MabionCD20 Compared to MabThera in Lymphoma Patients | Nov 12, 2015 | ― |
| Rituximab | Rheumatoid Arthritis | Phase III | Completed | MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis | Jun 09, 2015 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Mabioncd20 (Candidate Biosimilar To Rituximab), Mabthera®, Rituxan® | Phase III | Rheumatoid Arthritis | Withdrawn | MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis | Dec 02, 2020 | ― |
| Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone | Phase III | Diffuse Large B-Cell Lymphoma | Completed | MabionCD20 Compared to MabThera in Lymphoma Patients | Nov 12, 2015 | ― |
| Rituximab | Phase III | Rheumatoid Arthritis | Completed | MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis | Jun 09, 2015 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Mabion SA (DE:272) have in its pipeline
Mabion SA DE:272 is currently developing the following drugs: Mabioncd20 (Candidate Biosimilar To Rituximab), Mabthera®, Rituxan®, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.